About Regeneron
regeneron.com- Founded 1988
- Ticker REGN
REGN 609.94 USD -0.25%
- Revenue (FY2025) $14.34B
- Net income $4.50B
Investor research: Yahoo Finance · SEC filings
Source: Wikipedia
Regeneron
To apply for this job please visit regeneron.wd1.myworkdayjobs.com.
Working in Tokyo, Japan
Tokyo, officially the Tokyo Metropolis, is the capital and most populous city of Japan. The population of the city proper was over 14 million as of 2023. The Greater Tokyo Area, which includes Tokyo and parts of six neighboring prefectures, is the third-most populous metropolitan area in the world, with 33 million residents as of 2025.
What people say about Regeneron
- An effective eye drug is $50, but many doctors choose a $2,000 alternative
- Hospitals and universities repurposing drugs at lower cost
- FDA approves first gene therapy for treatment of genetic hearing loss
- FDA approves first gene therapy for treatment of genetic hearing loss
Recent news
- Regeneron pays $37M, adds $2B in biobucks to expand CytomX pact - Fierce Biotech
- A man for all markets returns to the Regeneron Science Talent Search - Society for Science
- How One Partnership Profit Line Reframes The Regeneron Pharmaceuticals Stock Story - Trefis
- Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy Now? - Yahoo Finance
- Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Aggregated from public discussions and news; opinions are the authors’ own.
More jobs at Regeneron
Keep exploring on Get A Job.ai
Not quite the right fit? Your next opportunity is a click away.
- Browse all jobs
- More jobs by category
- Remote jobs you can do from anywhere
- Research typical pay for this role
- Set a job alert so new matches reach you first
- Upload your resume to apply faster
Hiring instead? Post a job and reach candidates searching right now.